PEPTOKING
EN

Semaglutide fails to slow Alzheimer's disease in phase 3 evoke and evoke+ trials

Trial result

Novo Nordisk said its two phase 3 trials of oral semaglutide in 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer's disease did not show slower progression than placebo on the Clinical Dementia Rating Sum of Boxes after two years. Semaglutide improved some Alzheimer's-related biomarkers, but this did not translate into a delay in disease progression. Safety was consistent with earlier semaglutide trials.

Sources

  1. 01Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression(opens the source in a new tab) Novo Nordisk via GlobeNewswire
  2. 02Novo Nordisk announces topline results from the Evoke and Evoke+ trials of semaglutide in early AD(opens the source in a new tab) Alzheimer Europe

Peptides involved

  1. ApprovedSemaglutideGLP-1 receptor agonist31